WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at firstname.lastname@example.org or fill out the form on our website, http://www.weisslawllp.com/albany-molecular-research-inc/To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/weisslaw-llp-the-proposed-acquisition-of-albany-molecular-research-inc-may-not-be-in-the-best-interest-of-amri-shareholders-300471747.html SOURCE WeissLaw LLP
NEW YORK, June 9, 2017 /PRNewswire/ -- The proposed acquisition of Albany Molecular Research Inc. ("AMRI" or the "Company") (NASDAQ: AMRI) by affiliates Carlyle Group LP and GTCR LLC (the "Affiliates") is the subject of an investigation by WeissLaw LLP, a national class action and shareholders rights law firm. On June 6, 2017, the Company confirmed that it signed a definitive agreement under which the Affiliates will acquire all outstanding shares of the Company in a transaction valued at approximately $922 million, or $21.75 per share. WeissLaw is investigating whether AMRI's Board acted to maximize shareholder value prior to entering into the agreement. Notably, on May 9, 2017, AMRI reported it saw double-digit growth in first quarter of 2017. It reported total revenue of $163.8 million, representing an increase of $58.2 million or 55% when compared to the $105.6 million reported in the same period of the previous year. AMRI also reported an impressive 83% increase in EBITDA. Additionally, the per-share offer price represents a meager 9% premium over the Company's June 5 closing price. Finally, this deal will effectively privatize AMRI and exclude its shareholders from the Company's continued success and future growth prospects. Given these facts, WeissLaw is investigating whether AMRI's Board acted in the best interests of AMRI's public shareholders to maximize shareholder value prior to entering into the agreement. If you own AMRI shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubin by telephone at (888) 593-4771 or by email at email@example.com .